Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPA-KIDNEY Kids trial of empagliflozin in pediatric chronic kidney disease
NL-OMON58917Phase 3Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Change from Day 1 to Week 24 in urine albumin-creatinine ratio and Change from Day 1 to Week 24 in urine glucose. Started Jan 2026; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NL-OMON58917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58917.